共 50 条
- [32] Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes MellitusJOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (03) : 934 - 945Hamdouchi, ChafiqMaiti, PranabWarshawsky, Alan M.DeBaillie, Amy C.Otto, Keith A.Wilbur, Kelly L.Kahl, Steven D.Lewis, Anjana PatelCardona, Guemalli R.Zink, Richard W.Chen, KeyueSiddaramaiah, C. R.Lineswala, Jayana P.Neathery, Grace L.Bouaichi, CeciliaDiseroad, Benjamin A.Campbell, Alison N.Sweetana, Stephanie A.Adams, Lisa A.Cabrera, OverMa, XiaosuYumibe, Nathan P.Montrose-Rafizadeh, ChahrzadChen, YanyunMiller, Anne Reifel
- [33] LY2881835: a potent, efficacious and selective GPR40 agonist stimulates insulin and GLP-1 secretion normalising glucose levels in preclinical models of type 2 diabetesDIABETOLOGIA, 2012, 55 : S228 - S228Miller, A. ReifelCox, A.Briere, D.Marcelo, M.Rani, S. S. N.Padmaja, R.Wilbur, K.Osborne, E.Zink, R.Jett, D.Montrose-Rafizadeh, C.Michael, M.Bokvist, K.Matti, P.Hamdouch, C.
- [34] Xelaglifam, a novel GPR40/FFAR1 agonist, exhibits enhanced β-arrestin recruitment and sustained glycemic control for type 2 diabetesBIOMEDICINE & PHARMACOTHERAPY, 2024, 177Yoon, JongminLee, Don-GilSong, HaengjinHong, DahaePark, Ji SooHong, ChangheeAn, Kyung MiLee, Jung WooPark, Joon-TaeYoon, HongchulTak, JihoonKim, Sang Geon
- [35] Role of GPR40 in pathogenesis and treatment of Alzheimer's disease and type 2 diabetic dementiaJOURNAL OF DRUG TARGETING, 2019, 27 (04) : 347 - 354Chen, Jing-JingGong, Yu-HangHe, Ling
- [36] Identification of a Potent and Selective Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist with Favorable Physicochemical and in Vitro ADME PropertiesJOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (19) : 6691 - 6703Christiansen, ElisabethUrban, ChristianGrundmann, ManuelDue-Hansen, Maria E.Hagesaether, EllenSchmidt, JohannesPardo, LeonardoUllrich, SusanneKostenis, EviKassack, MatthiasUlven, Trond
- [37] Discovery of Potent and Selective Agonists for the Free Fatty Acid Receptor 1 (FFA1/GPR40), a Potential Target for the Treatment of Type II DiabetesJOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (22) : 7061 - 7064Christiansen, ElisabethUrban, ChristianMerten, NicoleLiebscher, KathrinKarlsen, Kasper K.Hamacher, AlexandraSpinrath, AndreasBond, Andrew D.Drewke, ChristelUllrich, SusanneKassack, Matthias U.Kostenis, EviUlven, Trond
- [38] The Role of GPR40 in Obesity and Type 2 Diabetes: A Study of Isolated Pancreatic Islets from Different Animal Models of DiabetesDIABETES, 2010, 59 : A457 - A457Balhuizen, AlexanderKumar, RajeshAbaraviciene, Sandra MeiduteAmisten, StefanOlde, BjornLundquist, IngmarSalehi, Albert
- [39] A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetesPHARMACOLOGY RESEARCH & PERSPECTIVES, 2016, 4 (06):Chen, YanyunSong, MinRiley, Jonathan P.Hu, Charlie C.Peng, XianbuScheuner, DonalynBokvist, KristerMaiti, PranabKahl, Steven D.Montrose-Rafizadeh, ChahrzadHamdouchi, ChafiqMiller, Anne Reifel
- [40] Pharmacokinetics (PK) and pharmacodynamics (PD) of the GPR40 agonist fasiglifam (TAK-875) and glimepiride following co-administration in type 2 diabetes subjectsDIABETOLOGIA, 2013, 56 : S353 - S353Viswanathan, P.Tsai, M.Lee, R. D.Vakilynejad, M.Zhang, W.Marcinak, J.Peng, X.